The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 27 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Physalis longifolia, it exhibits cytotoxic activity.
withaferin A inhibits the reaction [[ABCB1 protein results in decreased susceptibility to Doxorubicin] promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of ABCB1 mRNA]]
withaferin A inhibits the reaction [IL1B protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of ADAM17 protein]; withaferin A inhibits the reaction [TNF protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]
withaferin A results in decreased expression of BCL2 protein withaferin A inhibits the reaction [Cholesterol, Dietary results in decreased expression of BCL2 protein]
withaferin A results in decreased expression of BCL2L11 protein withaferin A inhibits the reaction [Cholesterol, Dietary results in increased expression of BCL2L11 protein]
withaferin A inhibits the reaction [Cholesterol, Dietary results in increased expression of CASP3 protein] withaferin A inhibits the reaction [Elements, Radioactive results in increased activity of CASP3 protein]
withaferin A inhibits the reaction [Cholesterol, Dietary results in decreased activity of CAT protein] withaferin A results in increased expression of CAT protein
withaferin A results in increased expression of CDH1 protein VIM protein mutant form inhibits the reaction [withaferin A results in increased expression of CDH1 protein]
withaferin A binds to CDKN1A protein withaferin A results in increased expression of CDKN1A mRNA withaferin A results in increased expression of and affects the localization of CDKN1A protein
CLDN1 protein results in decreased susceptibility to withaferin A withaferin A results in decreased expression of CLDN1 mRNA; withaferin A results in decreased expression of CLDN1 protein
DDIT3 mRNA affects the susceptibility to withaferin A withaferin A results in increased expression of DDIT3 protein Acetylcysteine inhibits the reaction [withaferin A results in increased expression of DDIT3 protein]
[withanone co-treated with withaferin A] results in decreased expression of HNRNPK protein; withaferin A binds to and results in decreased activity of HNRNPK protein
withaferin A binds to HSPA9 protein [withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein]] which affects the localization of and results in increased activity of TP53 protein; [withanone co-treated with withaferin A] results in decreased expression of HSPA9 protein; withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein]
withaferin A inhibits the reaction [IL1B protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL6 protein] withaferin A inhibits the reaction [Cholesterol, Dietary results in increased expression of IL6 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [withaferin A results in increased phosphorylation of MAPK1 protein]; [withanone co-treated with withaferin A] results in decreased expression of MAPK1 protein; Acetylcysteine inhibits the reaction [withaferin A results in increased phosphorylation of MAPK1 protein]; SOD2 protein inhibits the reaction [withaferin A results in increased phosphorylation of MAPK1 protein]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [withaferin A results in increased phosphorylation of MAPK3 protein]; [withanone co-treated with withaferin A] results in decreased expression of MAPK3 protein; Acetylcysteine inhibits the reaction [withaferin A results in increased phosphorylation of MAPK3 protein]; SOD2 protein inhibits the reaction [withaferin A results in increased phosphorylation of MAPK3 protein]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
MCL1 mutant form promotes the reaction [withaferin A results in increased cleavage of PARP1 protein] withaferin A results in increased expression of MCL1 protein
[withanone co-treated with withaferin A] results in decreased expression of MMP2 protein; VIM protein mutant form inhibits the reaction [withaferin A results in decreased expression of MMP2 protein]
withaferin A results in decreased expression of MMP9 protein VIM protein mutant form inhibits the reaction [withaferin A results in decreased expression of MMP9 protein]
[withaferin A results in increased phosphorylation of VIM protein] inhibits the reaction [NEDD9 protein binds to VIM protein]; withaferin A inhibits the reaction [NEDD9 protein binds to VIM protein] withaferin A results in decreased expression of NEDD9 protein
Dithiothreitol inhibits the reaction [withaferin A results in increased cleavage of PARP1 protein]; MCL1 mutant form promotes the reaction [withaferin A results in increased cleavage of PARP1 protein]
withaferin A inhibits the reaction [IL1B protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [TNF protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]
withaferin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; withaferin A inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
SOD2 protein inhibits the reaction [withaferin A results in increased phosphorylation of MAPK1 protein]; SOD2 protein inhibits the reaction [withaferin A results in increased phosphorylation of MAPK3 protein] withaferin A results in increased expression of SOD2 protein
withaferin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased localization of and results in increased activity of STAT1 protein]
withaferin A inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; withaferin A inhibits the reaction [TNF protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]] withaferin A results in decreased activity of TNF protein withaferin A inhibits the reaction [Cholesterol, Dietary results in increased expression of TNF protein]
withaferin A results in increased expression of TP53 mRNA [withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein]] which affects the localization of and results in increased activity of TP53 protein; withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein] withaferin A binds to TP53 protein
[withanone co-treated with withaferin A] results in decreased secretion of VEGFA protein; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VEGFA mRNA] withaferin A results in decreased expression of VEGFA protein
[withaferin A results in increased phosphorylation of VIM protein] inhibits the reaction [NEDD9 protein binds to VIM protein]; VIM protein mutant form inhibits the reaction [withaferin A results in decreased expression of CDH2 protein]; VIM protein mutant form inhibits the reaction [withaferin A results in decreased expression of MMP2 protein]; VIM protein mutant form inhibits the reaction [withaferin A results in decreased expression of MMP9 protein]; VIM protein mutant form inhibits the reaction [withaferin A results in increased expression of CDH1 protein]; withaferin A inhibits the reaction [NEDD9 protein binds to VIM protein] [withaferin A results in increased phosphorylation of VIM protein] inhibits the reaction [NEDD9 protein binds to VIM protein]; withaferin A inhibits the reaction [NEDD9 protein binds to VIM protein]
browse the term
